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Background-—Although estrogen receptor a (ERa) acts primarily as a transcription factor, it can also elicit membrane-initiated
steroid signaling. Pharmacological tools and transgenic mouse models previously highlighted the key role of ERamembrane-initiated
steroid signaling in 2 actions of estrogens in the endothelium: increase in NO production and acceleration of reendothelialization.
Methods and Results-—Using mice with ERa mutated at cysteine 451 (ERaC451A), recognized as the key palmitoylation site
required for ERa plasma membrane location, and mice with disruption of nuclear actions because of inactivation of activation
function 2 (ERaAF20 = ERaAF2!), we sought to fully characterize the respective roles of nuclear versus membrane-initiated steroid
signaling in the arterial protection conferred by ERa. ERaC451A mice were fully responsive to estrogens to prevent atheroma and
angiotensin II–induced hypertension as well as to allow flow-mediated arteriolar remodeling. By contrast, ERaAF20 mice were
unresponsive to estrogens for these beneficial vascular effects. Accordingly, selective activation of nuclear ERa with estetrol was
able to prevent hypertension and to restore flow-mediated arteriolar remodeling.
Conclusions-—Altogether, these results reveal an unexpected prominent role of nuclear ERa in the vasculoprotective action of
estrogens with major implications in medicine, particularly for selective nuclear ERa agonist, such as estetrol, which is currently
under development as a new oral contraceptive and for hormone replacement therapy in menopausal women. ( J Am Heart Assoc.
2018;7:e008950. DOI: 10.1161/JAHA.118.008950.)
Key Words: arteriolar remodeling • atherosclerosis • estrogen • hypertension • nuclear receptor
H ypertension affects 1 of 4 women worldwide, and itsprevalence is particularly high among women >60 years
of age. Indeed, the first decade after menopause is accom-
panied by an increase in blood pressure and has been
associated with a higher risk of cardiovascular diseases, such
as myocardial infarction and stroke.1 In line with these
epidemiological data, clinical and preclinical studies show
considerable evidence that estrogen modulates cardiovascular
physiological features and function.2 Even if the publication of
the Women’s Health Initiative in 20023,4 did not initially
confirm the expected protective action of estrogens against
coronary heart disease and questioned their overall benefit,
subgroup analysis suggested that women who initiated
hormone therapy soon after the onset of menopause had
reduced coronary artery events, in contrast to the increased
risk in more aged women.5 All experimental data demonstrate
major atheroprotective actions of estrogens. In particular,
17b-estradiol strongly prevents lipid deposition in mouse
models of atherosclerosis: apolipoprotein E–deficient6,7 and
low-density lipoprotein receptor–deficient (LDLr!/!)8 mice. In
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addition, in several experimental models of hypertension,
ovariectomy exacerbates, whereas estrogen replacement
attenuates, the course of hypertension9,10 and reduces arterial
stiffening associated with hypertension or aging.11 17b-
estradiol also increases basal nitric oxide (NO) production,12
accelerates reendothelialization,8,13 and prevents postinjury
medial as well as neointimal hyperplasia after vessel injury.14
Finally, 17b-estradiol plays a crucial role in the ability of
resistance arteries to remodel in response to a long-term
increase in blood flow, which is necessary to optimize tissue
perfusion.11,15
Two nuclear receptors, estrogen receptors (ERs) a and b,
have been reported to mediate cardiovascular protection
conferred by estrogens.16 ERb plays a key role in cardiac
protection,17 and ERa, especially in the endothelium, is involved
in the beneficial vascular actions of 17b-estradiol.18 Indeed,
most of the vascular actions of 17b-estradiol are abrogated in
mice lacking ERa in both endothelial and hematopoietic cells by
breeding Tie2-Cre transgenic mice (expressing the Cre recom-
binase under the control of the endothelial tyrosine-protein
kinase receptor (Tie2) promoter) with ERa-floxedmice at exon 2
(ERalox/lox).8,15,19 Thus, the endothelium, a guardian of arterial
integrity, represents a promising cellular target for 17b-
estradiol via the activation of ERa.18 Beside the well-recognized
role of nuclear ERa, which regulates target gene transcription
(genomic action) through activation functions (AFs) 1 and
2,16,20 a subpopulation of ERa is present at or near the plasma
membrane, where it can elicit rapid, nongenomic, membrane-
initiated steroid signaling (MISS) effects.21–25
Recently, we generated a mouse model in which mem-
brane ERa localization was abrogated by a point mutation of
the palmitoylation site of ERa (mice with ERa mutated at
cysteine 451 [ERa-C451A]), leading to an abrogation of
endothelial NO synthase (eNOS) phosphorylation and accel-
eration of reendothelialization in response to 17b-estradiol.22
The estrogen-dendrimer conjugate (EDC) and “pathway
preferential estrogens” (PaPEs) are highly effective in stimu-
lating nonnuclear signaling, but they are inefficient in
stimulating nuclear ER target gene expression.23,26 More
important, in vivo administration of EDC or PaPE-1 accelerates
repair of endothelial damage.23,26 In addition, EDC and PaPE-1
both favor the production of endothelial NO,22 a vasculopro-
tective agent of the arteries, initially viewed as an important
mechanism of the protective action of 17b-estradiol against
the development of atheroma and hypertension.27 Our arsenal
of pharmacological tools has recently been enriched with
estetrol, a fetal estrogen produced exclusively by the liver of
humans (and to a smaller extent in large apes). We
demonstrated that although estetrol nicely induced ERa
target gene transcription, it failed to promote eNOS activation
and to accelerate endothelial healing, but also antagonized
both of these 17b-estradiol MISS-dependent effects.28 Alto-
gether, these powerful pharmacological tools allow us to
uncouple nuclear and membrane actions of ERa with a
selective activation of MISS using PaPE-1 or EDC and of
nuclear ERa using estetrol. The novel understanding of action
of this new class of selective ER modulator–like molecules led
to the idea that they would decrease the proliferative action of
estrogens23,29 and, thereby, lower the risk of breast and/or
uterine cancer induced by sex hormones.30,31
In the present work, using these pharmacological tools of
gain of function (EDC, PaPE-1, and estetrol) and genetically
modified mouse models of ERa loss of function (Using mice
with ERa mutated at cysteine 451, recognized as the key
palmitoylation site required for ERa plasma membrane
location (ERaC451A), and mice with disruption of nuclear
actions because of inactivation of activation function 2
(ERaAF2!)), we sought to further explore the role of ERa
MISS in the prevention of atherosclerotic lesions and
hypertension and in the promotion of arteriolar remodeling,
3 crucial pathophysiological aspects of the vasculoprotective
actions of estrogens.
Methods
The data, analytical methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Mice
All procedures involving experimental animals were performed
in accordance with the principles and guidelines established
by the National Institute of Medical Research and were
approved by the local Animal Care and Use Committee. The
investigation conforms to the directive 2010/63/EU of the
European parliament. To generate the double-deficient mice,
Clinical Perspective
What Is New?
• Although most vasculoprotective effects studied until now in
mouse models were shown to be mediated by membrane
estrogen receptor a actions, the present results reveal that
experimental prevention against atheroma and hypertension
required only 17b-estradiol–mediated nuclear actions.
What Are the Clinical Implications?
• Estetrol, as a selective nuclear estrogen receptor a agonist
that does not alter circulating coagulation factors, could
now be considered as an alternative estrogen for women’s
health treatment in contraception or menopause.
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LDLr!/! female mice, purchased from Charles River (L’Ar-
bresle, France), were crossed with ERa-C451A+/! mice.22
ERa-AF20mice were generated, as previously described,32 and
were kindly provided by Professor P. Chambon (Strasbourg,
France). Mice are on a C57Bl/6 background, and genetically
manipulated mice are systematically compared with their
wild-type (WT) littermates controls (n=7–12 per group). For
short-term 17b-estradiol treatment, bilateral ovariectomy was
performed when the mice were 4 weeks old and then, 2 weeks
after surgery, mice were injected SC with either vehicle or
17b-estradiol (8 lg/kg). Mice were euthanized 6 hours after
the injection to study the short-term effect of 17b-estradiol
on gene expression. Before surgical and euthanasia proce-
dures, mice were anesthetized with a combination of
ketamine hydrochloride (100 mg/kg; Panpharma) and xyla-
zine (5 mg/kg; Sigma-Aldrich) by IP injection.
Real-Time NO Production
Aortas from intact mice (10–12 weeks/n=6 per group) were
quickly harvested and maintained in 200 lL Krebs-Ringer
oxygenated solution containing 2.5 mmol/L glucose at 37°C.
A NO-specific amperometric probe (ISO-NOPF100; World
Precision Instruments, Sarasota, FL) was implanted directly
in the tissue, and NO release was monitored. The aortas were
exposed to 17b-estradiol (10!8 mol/L) or vehicle (dimethyl
sulfoxide). The concentration of NO gas in the tissue was
measured in real time with the data acquisition system
LabTrax (World Precision Instruments) connected to the free
radical analyzer Apollo1000 (World Precision Instruments).
Data acquisition and analysis were performed with DataTrax2
software (World Precision Instruments). The NO-specific
amperometric probe was calibrated, as previously described.28
Analyses of Atherosclerosis Lesions
Bilateral ovariectomy was performed, as previously described.
Two weeks after surgery, mice were switched to a hyperc-
holesterolemic-atherogenic diet (1.25% cholesterol, 6% fat, no
cholate; TD96335; Harlan Teklad, Madison, WI) and concomi-
tantly received long-term estrogenic treatments. Mice were
implanted with subcutaneous pellets releasing either placebo
or 17b-estradiol (60-day release, 0.1 mg [ie, 80 lg/kg per
day]) at weeks 6 and 12. To evaluate the atheroprotective role
of selective activation of ERa MISS, mice received subcuta-
neous miniosmotic pumps (Alzet, model 2004; 0.25 lL/h,
28 days), releasing either empty dendrimer or EDC (240 lg/
kg per day); or pellet, releasing either a placebo or equivalent
dose of 17b-estradiol (pellet, 0.25 mg [ie, 240 lg/kg per
day]; Innovative Research of America, Sarasota, FL) or PaPE-1
(8.5-mg compound mixed with cholesterol to a total weight of
20 mg) at weeks 6 and 10. At the end of the protocol,
overnight fasted mice were anesthetized with a combination
of ketamine hydrochloride (100 mg/kg; Panpharma) and
xylazine (5 mg/kg; Sigma-Aldrich) via intraperitoneal injec-
tion, and blood was collected from retro-orbital venous
plexus. After euthanization, the heart, the thoracic aorta,
the liver, and the uterus were carefully dissected.
Lipid deposition size was estimated at the aortic sinus, as
previously described.8,32 Briefly, each heart was frozen on a
cryostat mount with optimal cutting temperature compound.
One hundred 10-lm-thick sections were prepared from the
top of the left ventricle, where the aortic valves were first
visible, up to a position in the aorta where the valve cusps
were just disappearing from the field. After drying for 2 hours,
the sections were stained with oil red O and counterstained
with Mayer’s hematoxylin. Ten sections of the 100, each
separated by 90 lm, were used for specific morphometric
evaluation of intimal lesions using a computerized Biocom
morphometry system. The first and most proximal section to
the heart was taken 90 lm distal to the point where the aorta
first becomes rounded. The mean lesion size (expressed in
lm2) in these 10 sections was used to evaluate the lesion size
of each animal.
En face aorta analyses were analyzed at 8 months of age.
The heart was perfusion fixed in situ with 10% phosphate-
buffered formalin for 10 minutes. After the perfusion, the
abdominal cavity was opened and the internal organs were
removed. The aorta from the arch to bifurcation was carefully
cleaned from periadventitial connective tissue. Then, the aorta
was opened longitudinally by an incision along its ventral
aspect. The thoracic and abdominal parts of the aorta were
pinned out flat (using 10-mm tips of dental root-canal
needles).
Determination of Plasma Lipids
Overnight fasted mice were anesthetized, and blood samples
were collected from the retro-orbital venous plexus. Total
plasma cholesterol was assayed using the CHOD-PAD kit
(Horiba ABX, Montpellier, France). The high-density lipoprotein
fraction was isolated from 10 lL of serum and assayed using
the “C-HDL+Third generation” kit (Roche, Lyon, France).
Analysis of mRNA Levels by Real-Time
Quantitative Reverse Transcription–Polymerase
Chain Reaction
Tissues were dissected and frozen. They were homogenized
using a Precellys tissue homogenizer (Bertin Technology,
Cedex, France), and total RNA from tissues was prepared
using Trizol reagent (Invitrogen, Carlsbad, CA). A total of
500 ng (aorta) or 1 lg (liver) was reverse transcribed for
10 minutes at 25°C and 2 hours at 37°C in a 20-lL final
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volume using the High Capacity cDNA reverse transcriptase
kit (Applied Biosystems). Real-time quantitative polymerase
chain reactions were performed on the StepOne instrument
(Applied Biosystems). Primers were validated by testing
polymerase chain reaction efficiency using standard curves
(95% ≤ efficiency ≤ 105%). Gene expression was quantified
using the comparative threshold cycle method; tumor protein,
translationally-controlled 1 (TPT1) (aorta) or Peptidyl-prolyl
cis-trans isomerase A (PPIA) (liver) was used as reference.
Blood Pressure Measurement
As previously shown,33 systolic blood pressure (SBP) was
measured every day using photoplethysmography (BP-2000
Blood Pressure Analysis System; Visitech Systems). Female
mice (aged 12–16 weeks) were divided into the following
groups: ERa!/!, ERa-C451A, and ERaAF20 mice associated
with their corresponding littermates. In all groups, mice were
acclimated to the technique for 2 weeks (week “!2” to “!1”)
before measuring basal SBP for 1 week (week “0”). Mice were
then subjected to sham operation or were implanted SC with
osmotic minipumps (Alzet, model 2004; 0.25 lL/h, 28 days)
releasing angiotensin II (AngII; 0.5 mg/kg per day; Bachem,
no. 4006473; solubilized in NaCl 0.9%) for 4 weeks to induce
hypertension.34 After surgery, mice were allowed to recover
for 3 to 5 days, and SBP was measured daily during 4 weeks.
The weekly average of SBP evolution pre- and post-AngII
treatment was represented as mean of 5 days of SBP
measurements (from week 0 to week 4). To assess the effect
of estetrol in AngII-treated mice, ovariectomy was performed
2 weeks before implantation of osmotic minipump containing
AngII and estetrol (AngII, 0.5 mg/kg per day, and estetrol,
6 mg/kg per day; solubilized in 50% PBS+50% dimethyl
sulfoxide). Surgery was performed under isoflurane (2%)
anesthesia. Analgesia was obtained with buprenorphine
(Temgesic; 0.1 mg/kg, SC) before and after surgery.
Histomorphometry
AngII arterial remodeling was evaluated on thoracic aorta.
Transverse aortic segments were dissected, embedded in
Tissue-tek (Sakura Finetek), and cut in 7-lm sections
(Cryostat CM3050 S; Leica). Orceine was used to stain
elastic fibers in the thoracic aorta media to measure media
thickness/surface and lumen surface. Image acquisition was
performed using Histolab, and measurements were performed
using ImageJ 1.47v.
Blood Flow–Mediated Arterial Remodeling
Increase in blood flow, applied to the mesenteric artery, was
performed, as previously described, on 4- to 5-month-old
female mice.15 Briefly, 3 consecutive first-order mesenteric
arteries were used, and surgery consisted of ligatures of
second-order branches. The artery located between the 2
ligated arteries was designated as the high-flow artery.
Arteries located at a distance of the ligated arteries were
used as controls (normal flow). After 14 days, mice were
euthanized and mesenteric arteries were collected. In each
protocol, animals were anesthetized with isoflurane (2.5%).
They were treated with buprenorphine (Temgesic; 0.1 mg/kg,
SC) before and after surgery. The protocol was approved by
the ethical committee (Protocol CEEA PdL 2012-105).
Flow-Mediated Dilation
First- or second-order mesenteric arterial segments were
isolated and mounted onto an arteriograph system (Living
System; LSI, Burlington, VT) in physiological saline solution
(37°C, pH 7.4; partial pressure of O2, 160 mm Hg; and partial
pressure of CO2, 37 mm Hg). This video-monitored perfusion
system allowed us to follow changes in arterial internal
diameter of pressurized arteries (Pression: 75 mm Hg; diam-
eter, 270 lm) after they were cannulated on glass microcan-
nulas connected to 2 peristaltic pumps, 1 controlling flow rate
and 1 under the control of a pressure-servo control system.35
Pressure at both ends of the artery segment was monitored
using pressure transducers. After the arteries were pressur-
ized at 75 mm Hg, a 20-minute equilibration period was
provided and endothelial function was assessed through
vasodilatory response to acetylcholine (1 lmol/L) after pre-
contraction with phenylephrine (10!6 mol/L). Arteries were
then washed and allowed to recover for 20 minutes. After an
equilibration period at low flow (3 lL/min) for 10 minutes,
arteries were precontracted (phenylephrine, 10!6 mol/L) and
step increases in intraluminal flow (2-minute step from 3–
50 lL/min) were generated through the distal pipette with a
peristaltic pump. The effect of estetrol on flow-mediated
dilation was evaluated ex vivo on arteries incubated with
estetrol (10!6 mol/L) for 30 minutes before assessing arterial
responses to flow. At the end of the experiment, arteries were
bathed in a Ca2+-free PSS containing ethylene-bis-(oxyethyle-
nenitrolo) tetra-acetic acid (2 mol/L) and sodium nitroprus-
side (10 lmol/L) to measure maximal passive diameter.36
Statistical Analyses
To test the respective roles of 17b-estradiol treatment and
genotype, a 2-way ANOVA was performed for atherosclerosis
experiment. When an interaction was observed between the 2
factors, the effect of 17b-estradiol treatment was studied in
each genotype using a Bonferroni post test. A 2-way ANOVA
for repeated measures was used for hypertension, flow-
mediated remodeling (FMR), and flow-mediated dilation
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experiments. To test the respective roles of 17b-estradiol and
EDC treatment, a 1-way ANOVA was performed, followed by a
Bonferroni post test. P<0.05 was considered statistically
significant.
Results
Short-Term 17b-Estradiol Treatment Induces
Transcriptional Response But Not NO Production
in Aorta From ERa-C451A Mice
To evaluate the potential cross talk between MISS and nuclear
ERa in blood vessels, we first compared gene expression
profiles in the aorta from ERa!/!, ERa-C451A, and ERaAF20
mice, including their littermate controls, after short-term 17b-
estradiol administration (6 hours). Two genes among the
most induced by 17b-estradiol in the aorta32,37 (ie, Gremlin 2
and UDP-N-acetyl-a-d-galactosamine:polypeptide N-acetylga-
lactosaminyltransferase-like 2) were analyzed. Their transcrip-
tional regulation is entirely ERa dependent because no gene
regulation was observed in aortas from ERa!/! mice
(Figure 1A). Similarly, induction of these ERa target genes
was totally abrogated in ERaAF20 mice, whereas targeting
membrane ERa, in ERa-C451A mice, has a minor impact,
affecting only modestly the most regulated gene by 17b-
estradiol, Gremlin 2 (Figure 1A). By contrast, although 17b-
estradiol (10!8 mol/L) rapidly induced NO production by
aorta in WT mice, it failed to induce NO production in aorta
from ERa-C451A mice (Figure 1B). These results further
demonstrate that, in ERa-C451A mice, eNOS activation in
response to 17b-estradiol is abrogated, indicating the aboli-
tion of ERa MISS, whereas nuclear ERa activity in the arterial
wall is preserved.
By Contrast With Nuclear ERa-AF2, ERa MISS Is
Neither Necessary Nor Sufficient for Estrogen-
Mediated Atheroprotection
We then investigated the role of ERa MISS actions on arteries
submitted to an atherogenic stress using ERa-C451A mice
bred with LDLr!/! mice (Figure 2A). As expected, ovariec-
tomy led to uterine atrophy, whereas exogenous 17b-estradiol
replacement induced uterine hypertrophy in both ERa-WT/
LDLr!/! and ERa-C451A/LDLr!/! mice (Figure 2B and 2C).
In addition, 17b-estradiol treatment similarly decreased fatty
streak deposits at the aortic sinus of both ERa-WT/LDLr!/!
and ERa-C451A/LDLr!/! mice (Figure 2D and 2E). Accord-
ingly, gene expression of atherosclerosis markers, such as
vascular cell adhesion molecule 1 or Monocyte Chemoat-
tractant Protein-1 (MCP-1), was decreased in 17b-estradiol–
treated mice aorta, irrespective of the genotype (Figure 2F).
As expected, 17b-estradiol significantly decreased choles-
terolemia in ovariectomized ERa-WT/LDLr!/! mice and in
ERa-C451A/LDLr!/! mice (Figure 2G).
In addition, endogenous estrogens decreased the lesion
size on later stages of atheroma, as demonstrated by analysis
of “en face” preparations of the aortic tree from 8-month-old
ovariectomized versus sham-operated female WT mice (Fig-
ure 3A). This protective effect was abolished in ERaAF20/
LDLr!/! mice (Figure 3B), confirming that atheroprotection
required nuclear ERa, as previously shown in aortic sinus at
earlier stages.32 However, compared with ERa-WT/LDLr!/!
mice, endogenous 17b-estradiol similarly prevented atheroma
in intact ERa-C451A/LDLr!/! mice, demonstrating that ERa
MISS is fully dispensable for the atheroprotective effect of
endogenous estrogens (Figure 3C).
We then assessed whether selective activation of ERa
MISS was sufficient to prevent early atheroma in LDLr!/!
mice under an atherogenic diet using 2 unique pharmacolog-
ical tools: PaPE-1 and EDC. As previously described, these 2
molecules did not induce uterine hypertrophy (Figure 4A and
4B) but were able to induce transcriptional responses, such as
increase in adiponectin mRNA level in the liver (Figure 4C), as
previously reported.26 However, although 17b-estradiol
decreases plasma cholesterol, PaPE-1 or EDC do not
(Figure 4D). In addition, doses of EDC or PaPE-1, previously
shown to accelerate reendothelialization,23,26 did not prevent
lipid deposition at the aortic sinus from LDLR!/! mice fed a
hypercholesterolemic diet (Figure 4E and 4F). By contrast,
equivalent dose of 17b-estradiol prevented atheroma depo-
sition by up to 70%. Altogether, the use of both genetically
deficient mice and pharmacological tools consistently demon-
strated that ERa MISS is neither necessary nor sufficient for
the atheroprotective effect mediated by ERa activation, by
contrast with nuclear ERaAF2.
Endogenous Estrogens Prevent Hypertension in
ERa-C451A Mice But Not in ERa-AF20 Mice
We then explored the role of ERa MISS actions in animals
submitted to hypertensive stress. Endogenous estrogens
protected WT female mice from AngII-induced hypertension,
as demonstrated by a greater increase in SBP in ovariec-
tomized mice than in intact mice (Figure S1A). We then
evaluated the respective protective role of ERa, ERa MISS,
and nuclear ERa in AngII-induced hypertension using ERa!/!,
ERa-C451A, and ERa-AF20 intact mice and their respective
littermate controls (Figure 5A). In the different WT littermate
control mice, 4 weeks of AngII infusion increased SBP. The
hypertensive effect of AngII was significantly exacerbated in
ERa!/! mice (Figure 5B) but not in ERb!/! mice (Figure S2),
showing that the beneficial effect of endogenous estrogens is
ERa dependent. Moreover, the blood pressure increase
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Figure 1. 17b-Estradiol (E2) induces transcriptional response but not NO production in aorta from estrogen receptor a mutated at cysteine
451 (ERa-C451A) mice. A, Four-week-old ovariectomized ERa!/!, deficient for activation function-2 ERa-AF20, and ERa-C451A mice or their
respective littermates control mice (n=7–9 per group) received short-term E2 subcutaneous injection. Six hours after, mRNA levels of the
indicated gene from aorta were quantified by real-time quantitative polymerase chain reaction and normalized to TPT1 mRNA levels. Results
are expressed according to the level in aorta from vehicle-treated ERa–wild type (WT) set as 1. B, Representative trace of ex vivo
amperometric measurements of NO release of aorta from 10- to 12-week-old ERa-C451A or their littermate control mice exposed to E2
(10!8 mol/L) and area under the curve (AUC) quantification. Results are expressed as means"SEM. To test the respective roles of E2
treatment and genotype, a 2-way ANOVA was performed. When an interaction was observed between the 2 factors, effect of E2 treatment
was studied in each genotype using a Bonferroni post test. AU indicates arbitrary unit; DMSO, dimethyl sulfoxide; Gatnl2, UDP-N-acetyl-a-d-
galactosamine:polypeptide N-acetylgalactosaminyltransferase-like 2; Grem2, Gremlin 2; NS, not significant. ***P<0.001.
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Figure 2. 17b-Estradiol (E2) decreases fatty streak deposits at the aortic sinus in estrogen receptor a mutated at
cysteine 451 (ERa-C451A)/low-density lipoprotein receptor–deficient (LDLr!/!) mice. A, Four-week-old ovariec-
tomized ERa–wild-type (WT)/LDLr!/! and ERa-C451A/LDLr!/! mice were given either placebo or E2 during
12 weeks and switched to an atherogenic diet from the age of 6 to 18 weeks (n=7–10). Representative uteri (B),
uterine weights (C), representative micrographs of oil red O lipid-stained cryosections of the aortic sinus (D), and
quantification of lipid deposition (E) and vascular cell adhesion molecule (VCAM-1) and MCP1 mRNA levels from
aorta, quantified by real-time quantitative polymerase chain reaction and normalized to TPT1 mRNA levels (F) and
cholesterol content (G) from these mice.
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Figure 3. The atheroprotective effect of endogenous estrogens persists in 8-month-old estrogen receptor amutated at cysteine 451
(ERa-C451A)/low-density lipoprotein receptor–deficient (LDLr!/!) mice, whereas it is abolished in ERa-AF20/LDLr!/!mice. A, Four-
week-old mice (n=5–7) were ovariectomized (OVX) or not (SHAM) and switched to atherogenic diet from the age of 6 weeks until
euthanasia. Representative en face aorta preparations are shownwith respective quantification of lesions fromdescending aorta of ERa-
AF20/LDLr!/! (B) or ERa-C451A/LDLr!/! (C) mice and their respective littermates. Data are mean " SEM. WT indicates wild type.
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Figure 4. Selective activation of estrogen receptor a membrane-initiated steroid signaling does not prevent early plaque
formation. Four-week-old ovariectomized low-density lipoprotein receptor–deficient mice were given 17b-estradiol (E2),
pathway preferential estrogen (PaPE)-1 pellet or vehicle (Veh), or empty dendrimer (Dend) or estrogen-Dend conjugate
(EDC) (n=6–9) and switched to an atherogenic diet from the age of 6 to 14 weeks. Representative uteri (A), uterine weight
(B), adiponectin mRNA levels from liver quantified by real-time quantitative polymerase chain reaction and normalized to
PPIA mRNA levels (C), plasma cholesterol content (D), representative micrographs of oil red O lipid-stained cryosections of
the aortic sinus (E), and quantification of lipid deposition from these mice (F). Data are mean " SEM. To test the impact of
the different treatments, a 1-way ANOVA was performed. *P <0.05 , ***P <0.001.
DOI: 10.1161/JAHA.118.008950 Journal of the American Heart Association 9
Membrane vs Nuclear ERa in Arterial Effects Guivarc’h et al
O
R
IG
IN
A
L
R
E
SE
A
R
C
H
 by guest on June 30, 2018
http://jaha.ahajournals.org/
Downloaded from 
****
***
B
D
C F
E
G
Sham AngII 
Sham AngII 
Sham AngII 
20
40
60
80
100
120
140
160
ERαAF2+/+ ERαAF20
*
*
**
M
ed
ia
/L
um
en
 ra
tio
 n
or
m
al
iz
ed
 
ER
α
AF
2+
/+
ER
α
AF
20
ER
α
-/-
ER
α
+/
+
20
40
60
80
100
120
140
160
ERα-/-
Sham AngII
*
**
**
M
ed
ia
/L
um
en
 ra
tio
 n
or
m
al
iz
ed
 
ERα+/+
0
20
40
60
80
100
120
140
160
ERαWT ERαC451A
*
0 1 2 3 4
90
100
110
120
130
140
150
160
170
180
Weeks
***
###
#
***
###
SB
P 
(m
m
H
g)
 
ERαAF2+/+
ERαAF2+/+ + Ang II 
ERαAF20
ERαAF20 + Ang II
0 1 2 3 4
90
100
110
120
130
140
150
160
170
180
Weeks
***
**
###
#
**
###
SB
P 
(m
m
H
g)
 
0 1 2 3 4
90
100
110
120
130
140
150
160
170
180
Weeks
* ***S
BP
 (m
m
H
g)
 
ERα+/+
ERα+/+ + Ang II 
ERα-/- 
ERα-/- + Ang II 
ERαWT
ERαWT+ Ang II 
ERαC451A
ERαC451A+ Ang II
ER
α
W
T
ER
α
C4
51
A
M
ed
ia
/L
um
en
 ra
tio
 n
or
m
al
iz
ed
 
Sham AngII
Sham AngII
0 -2
Habituation 
Mini osmotic pump releasing AngII (0.5 mg/kg/day) 
Basal SBP 
4 
Weeks 
4-month-old
A
Daily SBP measurment 
*P<0.05; **P<0.05; ***P<0.001 AngII vs. respective sham; #P<0.05; ###P<0.001 WT vs mutant mice
Figure 5. Endogenous estrogens prevent hypertension and medial remodeling in estrogen receptor amutated at cysteine 451
(ERa-C451A)mice but not in ERa-AF20mice. A, Intact femalemicewere implantedwith osmoticminipumps delivering angiotensin
II (AngII; 0.5 mg/kg per day, 1 month). Mean of systolic blood pressure (SBP) measurements for 5 days was represented as
weekly evolution of blood pressure pre-AngII treatment (week 0) and post-AngII treatment (weeks 1–4). SBP measurements (B
through D) and andmedial remodeling (E through G) from thoracic aorta were evaluated in ERa!/! (n=8; B and E), ERa-AF20 (n=7;
C and F), ERa-C451A (n=7; D and G) intact mice and their respective littermate controls (n=7). WT indicates wild type.
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induced by AngII infusion was significantly greater in ERa-
AF20 mice than in WT mice (Figure 5C), demonstrating that
the nuclear ERaAF2 is necessary for the protective effect of
ERa in hypertension. By contrast, the increase in blood
pressure was similar in ERa-C451A and WT mice, demon-
strating the dispensable role of membrane ERa in this process
(Figure 5D). Histomorphometric analysis showed the absence
of aortic smooth muscle hypertrophy in intact WT mice
treated with AngII, contrasting with the media remodeling in
ovariectomized WT mice given AngII (Figure S1B). Interest-
ingly, AngII treatment led to arterial remodeling in ERa!/!
and ERa-AF20, but not in ERa-C451A, intact mice (Figure 5E
through 5G), confirming that aortic structural changes paral-
leled the level of hypertension. Because hypertension was
induced by AngII, we measured the gene expression level of
the angiotensin-converting enzyme (Ace) and angiotensin-
converting enzyme 2 (Ace2) and of the AngII type 1 receptors
(AT1Ra and AT1Rb) in arteries isolated, and we found no
difference in expression level in ERa!/!, ERa-C451A, and
ERa-AF20 compared with WT mice (Figure S3).
Endogenous Estrogens Allow Flow-Mediated
Arteriolar Remodeling in ERa-C451A Mice But
Not in ERa-AF20 Mice
Besides pressure-associated medial hypertrophic remodeling
that characterizes hypertension, at the level of arterioles,
outward remodeling occurs in response to increased blood
flow and shear stress at the surface of endothelial cells. This
remodeling is essential in postischemic revascularization or
collateral artery growth.38 To better characterize the respec-
tive role of nuclear versus ERa MISS in this remodeling, we
investigated in vivo FMR of resistance arteries from ERa-AF20
and ERa-C451A mice. Two weeks after arterial ligation,
arterial diameter was determined in vitro in response to
stepwise increases in intraluminal pressure (Figure 6A). As
expected, passive arterial diameter was significantly higher in
high-flow than in normal-flow arteries in WT (Figure 6B), but
not in ERa!/!, mice (Figure 6C). Interestingly, the effect of
endogenous estrogens on FMR was normal in ERa-C451A
(Figure 6D), whereas it was completely abrogated in ERaAF20
(Figure 6E), highlighting the crucial role of nuclear ERa in
FMR.
Selective Activation of Nuclear ERa Using
Estetrol Prevents AngII-Induced Hypertension
and Favors Flow-Mediating Remodeling
Because nuclear ERa appears to be crucial to the prevention
of atheroprotection and hypertension as well as to allow
FMR, we decided to evaluate the impact of estetrol
(Figure 7A). This natural selective ER modulator–like
molecule was recently recognized to activate selectively
nuclear ERa and to be devoid of vascular MISS action.28 We
also previously demonstrated that estetrol conferred athero-
protection.28 In addition, although short incubation with
estetrol was not able to modulate the acute vasodilating
response to flow (Figure 7B), a long-term treatment with
estetrol allowed flow arteriolar remodeling to occur in
ovariectomized mice (Figure 7C). Estetrol also prevented
the increase in SBP induced by AngII treatment in ovariec-
tomized mice (Figure 7D). These data clearly show that
nuclear ERa activation is sufficient to attenuate AngII-induced
hypertension and to promote FMR.
Discussion
Estrogen effects are mainly mediated by ERa, which acts
primarily as a nuclear receptor/transcriptional factor, but
which can also elicit rapid MISS. Because ERa MISS is
necessary and sufficient to increase NO production and to
accelerate postinjury reendothelialization without impact on
sex targets, it was initially proposed that selective activation
of membrane ERa could confer arterial protection with
minimal risk of uterine or breast cancer.23,26 In the present
study, we investigated the role of ERa eliciting membrane
actions in the prevention of atheroma and hypertension as
well as in the promotion of arteriolar outward remodeling.
First, we addressed the question of the necessary role of
ERa MISS on 3 major vasculoprotective effects of estrogens.
To this aim, on the basis of in vitro work demonstrating that
the palmitoylation site at Cys447 of human ERa (the mouse
counterpart of ERa Cys451) is crucial for the membrane
localization of ERa,39 we generated a mouse model with a
point mutation of this amino acid (ERa-C451A).22 The
decrease of membrane localization of ERa was confirmed in
primary hepatocytes and resulted in female infertility, an
increase in luteinizing hormone levels, and hemorrhagic
ovaries lacking corpora lutea.22 By contrast, the transcrip-
tional action of 17b-estradiol on the uterus was preserved:
gene expression was similar in ERa-C451A and WT mice.22
Herein, we show that the impact of MISS on short-term 17b-
estradiol–dependent gene regulation in the aorta is also
minimal, extending the previous observation to an arterial
tissue. We also demonstrate that palmitoylation of ERa-C451,
and thereby the activation of ERa MISS, is dispensable for the
prevention by 17b-estradiol of early stages of atheroma
development at the aortic sinus, but also of more advanced
lesions on the thoracic and abdominal aorta.
In addition, long-term treatment with AngII induced a
significantly higher increase in SBP and media aortic hyper-
trophy in the absence of endogenous estrogens (ovariec-
tomized mice) or of ERa (ERa!/! mice). Our finding is in
agreement with previous works showing that hypertension
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Figure 6. Endogenous estrogens allow flow-mediated outward remodeling of resistance arteries in estrogen receptor a mutated at cysteine
451 (ERa-C451A) mice but not in ERa-AF20 mice. A, Arterial diameter was measured in response to stepwise increases in pressure in
mesenteric arteries submitted chronically to high flow (HF) or to normal flow (NF). Arteries were isolated from wild-type (n=12; B), ERa!/!
(n=8; C), ERa-C451A (n=5; D), or ERa-AF20 (n=7; E) mice. NS indicates not significant.
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induced by AngII is lower in female than in male mice.40,41 The
protective effect of 17b-estradiol is, at least in part, mediated
by the AngII type 2 receptor.42 This receptor is counteracting
the effect of the type 1 receptor with vasodilator effect not
subjected to desensitization,43 although in hypertension, this
balance is not necessarily in favor of a vasodilator tone.44,45
The measurement of blood pressure in mice using plethys-
mography (tail cuff) can be considered as a limitation,
because this technique is less accurate than telemetry.
However, this limitation has to be taken with caution as
regard to baseline or central blood pressure with the tail cuff
method and some concern about the impact of the surgery for
telemetry.46 Nevertheless, the increase in pressure induced
by AngII is the same whether it is measured using plethys-
mography or telemetry.46 Our work is in agreement with
previous works showing that ERa was involved in the
protective effect of 17b-estradiol against AngII-induced
hypertension.47 Interestingly, a protective role for ERa has
been also suggested in pulmonary hypertension.48 The
present study definitively demonstrates the role of ERa in
this beneficial effect of endogenous estrogens independently
on ERa MISS.
Nevertheless, a role for ERb has been also shown in basal
arterial blood pressure. Indeed, basal arterial blood pressure
increases more in ERb!/! mice during aging than in age-
matched control mice.49 In addition, the pharmacological
activation of ERb leads to blood pressure lowering in
spontaneously hypertensive rats with reduced myocardial
hypertrophy.50 Arias-Loza et al also show that both ERa and
ERb activation attenuates cardiovascular remodeling in aldos-
terone salt-treated rats.51 In the present study, we observed
no protective role of ERb against AngII-mediated hypertension
in adult female mice (Figure S2). Thus, both ERa and ERb could
contribute to the control of arterial blood pressure, according
to the context (aging versus AngII-induced hypertension), and
their precise role and how they interact remain to be further
investigated. In addition, beside ERs, G protein-coupled
estrogen receptor 1 (GPER), has emerged as a third ER.
Despite conflicting results obtained with the different mice
models of GPER inactivation,52 GPER activation has been
reported to exert several beneficial effects in the cardiovas-
cular system, including protection against atherosclerosis and
hypertension.53,54 Treatment with the selective agonist G-1
reduces atherosclerosis in ovariectomized mice, and the
beneficial effects of GPER in this model are associated with a
reduction in macrophage and T-cell recruitment, indicating an
anti-inflammatory mechanism.55 In addition, activation of
GPER has been reported to protect female mice from salt-
and pressure-induced vascular damage.56,57 Altogether,
although activation of nuclear, but not membrane, ERa is
necessary to induce a protection against atherosclerosis and
hypertension, we cannot exclude the participation of other
membrane-initiated steroid signal elicited through GPER-
mediated pathway.
Because hypertension is a major risk factor for cardiovas-
cular diseases and especially for ischemic disorders, we also
investigated FMR, which has a major role in the homeostasis
of tissue perfusion. Indeed, FMR consists of vascular
enlargement or outward remodeling induced by flow (shear
stress) in small collateral arteries surrounding ischemic
areas.38 It contributes to the prevention of further tissue
injury (eg, in limb or myocardial ischemia). FMR has been
shown to be reduced by hypertension,58,59 diabetes melli-
tus,60,61 and aging.11,62 More important and rather unexpect-
edly, we previously reported that FMR depends on the
presence of ERa15,63 and could contribute to the better
resistance to ischemia/necrosis of female compared with
male mice. Herein, we report that ERa MISS is also
dispensable to mediate this beneficial action of estrogens.
We previously demonstrated22 and confirmed herein, using
another experimental approach, that ERa MISS is critical for
the production of NO. Because NO is a well-recognized
vasculoprotective mediator and guardian of arterial integ-
rity,27 and because 17b-estradiol stimulates endothelial NO
production through ERa MISS activation,22 one of the main
surprises and unexpected findings in the present study is the
absence of a role of ERa MISS on vascular protection. Indeed,
it is largely believed that the increase in endothelium-derived
NO plays an important role in the vasculoprotective actions of
estrogens, in particular in their atheroprotective action.18,64
Interestingly, present finding is strikingly consistent with our
previous work published 20 years ago, reporting that the
atheroprotective effect of exogenous 17b-estradiol was not
altered by NOS inhibition.65 Maeda’s group subsequently
refined this conclusion using hypercholesterolemic eNOS!/!
mice, showing that eNOS gene inactivation favored atheroma
through hypertension, whereas the lack of local endothelial
NO after blood pressure normalization did not contribute to
the atheroprotective effect of 17b-estradiol.66 In addition, the
absence of caveolin-1, which is involved in ERa-associated
eNOS activation at the level of the plasma membrane, had no
impact on FMR.67
Then, in addition to genetic model of loss of function,
pharmacological tools, such as PaPE and EDC, represent a
complementary approach to evaluate ERa MISS action.
Contrary to their stimulatory action on reendothelialization
and on NO production,22,23 none of these molecules was able
to prevent atheroma LDLr!/! mice. Interestingly, a similar
finding was previously reported in EDC-treated apolipoprotein
E–deficient mice.68 Accordingly, we previously showed that
17b-estradiol failed to induce any atheroprotective action
using mouse model in which nuclear effects are abrogated
(ERa-AF20/LDLr!/! mice), highlighting the requirement of
nuclear/transcriptional actions of ERa for early
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atheroprotection at the level of the aortic sinus.32 Herein, we
further extend the crucial role of ERaAF2 in atheroma
prevention by endogenous estrogens through en face analysis
of the thoracic and abdominal aorta (ie, in arterial sites where
the shear stress is less dramatically altered compared with
that at the aortic sinus). Moreover, the present study allows
us to identify the crucial role of ERaAF2 in the protective
effect of estrogens against high blood pressure and to
promote FMR. In line with the genetic approach showing the
necessary role of nuclear ERa, the response of estetrol, which
has an unusual profile of ERa activation, and uncoupling
nuclear and membrane activation28 demonstrate the vascu-
loprotective potential of nuclear ERa activation alone. Indeed,
we previously reported the potent atheroprotective effect of
estetrol28 as well as its capacity to prevent neointimal
hyperplasia after endovascular femoral artery injury.14 Herein,
we show that estetrol prevents hypertension and vascular
hypertrophy induced by AngII and allows FMR. These exper-
imental data complement previous clinical studies reporting
that estetrol has less effect than ethinyl-estradiol on hepatic-
derived hemostatic biomarkers69 and, therefore, could be the
only oral estrogen that does not increase the risk of
thromboembolic events. Because estetrol, in combination
with a progestin, is able to block ovulation, this fetal estrogen
is being evaluated as both a new contraceptive and a new
hormonal treatment for menopause.69
To conclude, the combination of genetically modified
mouse models (membrane and nuclear loss of function) and
pharmacological approaches (membrane and nuclear gain of
function) is unique in the area of nuclear receptors. This
combination has led to the following conclusions, summarized
in Figure 8: (1) ERa MISS is necessary and sufficient to
promote 2 short-term actions of 17b-estradiol on the
endothelium: the acceleration of endothelial wound healing,
which involves mainly endothelial cell migration,70 and the
increase in endothelial NO production. (2) By contrast, ERa
MISS is neither necessary nor sufficient for eliciting the long-
term effect of estrogens on arteries (ie, protection against
neointimal hyperplasia,14 atheroma,28 hypertension, and
induction of FMR). (3) Accordingly, the nuclear ERa activation
elicited by estetrol (that does not activate ERa MISS) is
sufficient to confer these 4 major vasculoprotective actions.
These results shed a new light on the mechanisms of the
vasculoprotective effects of estrogens and will help to
understand the tissue-specific actions of selective ER mod-
ulators, one of the major mysteries of ER biological features.
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dendrimer conjugate; and PaPE, pathway preferential estrogen.
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Figure S1. Effect of estrogen depletion on systolic blood pressure and aortic remodeling.
(A) Systolic blood pressure measurements in intact wild type (WT) and in ovariectomized (OVX) mice
implanted with osmotic minipumps delivering angiotensin II (AngII, 500 ng/kg per day, 1 month) to induce
hypertension or sham operated (Sham). (B) Media/Lumen Ratio and (C) Representative images of aortic
remodeling in WT and WT-OVX mice.
Values are presented as mean ± SEM (n=6), and statistically compared to respective control group. *:
p<0.05; **: p<0.01 ***: p<0.001 Ang II vs respective sham ; # # p<0.01 WT vs WT-OVX.
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Figure S2. Effect of the absence of estrogen receptor beta (ERbeta) on systolic blood pressure in mice
Systolic blood pressure measurements in intact wild type (ERbeta +/+) and in mice lacking ERbeta (ERbeta
-/-) mice implanted with osmotic minipumps delivering angiotensin II (AngII, 500 ng/kg per day, 1 month)
to induce hypertension or sham operated.
Values are presented as mean ± SEM (n=6 per group), and statistically compared to respective control
group. *: p<0.05; Ang II vs respective control
*
*
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Figure S3. Gene expression level of the angiotensin converting enzymes Ace and Ace2 and of the
angiotensin II type 1 receptor (AT1Ra and AT1Rb) measured in intact wild type (WT) and in ERa-/-,
ERaC451A and ERaAF20 mice. Values are presented as mean ± SEM (n=5 per group), and statistically
compared to the WT group. No siginficant difference was observed between groups.
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